Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Application filed to market Bronchitol for CF in Europe

An application has been filed with the European Medicines Agency (EMeA) to market Bronchitol in Europe for the treatment of cystic fibrosis.

Pharmaxis to acquire Topigen Pharmaceuticals Inc.

Pharmaxis has announced an agreement to acquire Canadian based private biopharmaceutical company Topigen Pharmaceuticals Inc.

FDA Advisory Committee recommends approval of Aridol

The Advisory Committee of the FDA has voted to recommend the approval of Aridol for use as a bronchial test to assess bronchial hyperresponsiveness to aid in diagnosing patients who have symptoms of asthma or symptoms that are suggestive of asthma. (Australian pack shot shown)

Sustained benefit with Bronchitol in Phase 3 CF trial

Significant headline results have been announced for the second six-month dosing Phase 3 trial of Bronchitol in people with cystic fibrosis.

Copyright 2010 © Pharmaxis Ltd. All rights reserved  |  Powered by Siteflex CMS

• Sitemap
• Useful Links
• Glossary